IBDEI26U ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,36741,1,4,0)
 ;;=4^D58.8
 ;;^UTILITY(U,$J,358.3,36741,2)
 ;;=^267984
 ;;^UTILITY(U,$J,358.3,36742,0)
 ;;=D58.2^^169^1858^8
 ;;^UTILITY(U,$J,358.3,36742,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36742,1,3,0)
 ;;=3^Hemoglobinopathies NEC
 ;;^UTILITY(U,$J,358.3,36742,1,4,0)
 ;;=4^D58.2
 ;;^UTILITY(U,$J,358.3,36742,2)
 ;;=^87629
 ;;^UTILITY(U,$J,358.3,36743,0)
 ;;=C83.10^^169^1859^52
 ;;^UTILITY(U,$J,358.3,36743,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36743,1,3,0)
 ;;=3^Mantle cell lymphoma, unspecified site
 ;;^UTILITY(U,$J,358.3,36743,1,4,0)
 ;;=4^C83.10
 ;;^UTILITY(U,$J,358.3,36743,2)
 ;;=^5001561
 ;;^UTILITY(U,$J,358.3,36744,0)
 ;;=C83.19^^169^1859^51
 ;;^UTILITY(U,$J,358.3,36744,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36744,1,3,0)
 ;;=3^Mantle cell lymphoma, extranodal and solid organ sites
 ;;^UTILITY(U,$J,358.3,36744,1,4,0)
 ;;=4^C83.19
 ;;^UTILITY(U,$J,358.3,36744,2)
 ;;=^5001570
 ;;^UTILITY(U,$J,358.3,36745,0)
 ;;=C83.50^^169^1859^45
 ;;^UTILITY(U,$J,358.3,36745,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36745,1,3,0)
 ;;=3^Lymphoblastic (diffuse) lymphoma, unspecified site
 ;;^UTILITY(U,$J,358.3,36745,1,4,0)
 ;;=4^C83.50
 ;;^UTILITY(U,$J,358.3,36745,2)
 ;;=^5001581
 ;;^UTILITY(U,$J,358.3,36746,0)
 ;;=C83.59^^169^1859^46
 ;;^UTILITY(U,$J,358.3,36746,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36746,1,3,0)
 ;;=3^Lymphoblastic lymphoma, extrnod and solid organ sites
 ;;^UTILITY(U,$J,358.3,36746,1,4,0)
 ;;=4^C83.59
 ;;^UTILITY(U,$J,358.3,36746,2)
 ;;=^5001590
 ;;^UTILITY(U,$J,358.3,36747,0)
 ;;=C83.70^^169^1859^12
 ;;^UTILITY(U,$J,358.3,36747,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36747,1,3,0)
 ;;=3^Burkitt lymphoma, unspecified site
 ;;^UTILITY(U,$J,358.3,36747,1,4,0)
 ;;=4^C83.70
 ;;^UTILITY(U,$J,358.3,36747,2)
 ;;=^5001591
 ;;^UTILITY(U,$J,358.3,36748,0)
 ;;=C83.79^^169^1859^11
 ;;^UTILITY(U,$J,358.3,36748,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36748,1,3,0)
 ;;=3^Burkitt lymphoma, extranodal and solid organ sites
 ;;^UTILITY(U,$J,358.3,36748,1,4,0)
 ;;=4^C83.79
 ;;^UTILITY(U,$J,358.3,36748,2)
 ;;=^5001600
 ;;^UTILITY(U,$J,358.3,36749,0)
 ;;=C81.00^^169^1859^61
 ;;^UTILITY(U,$J,358.3,36749,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36749,1,3,0)
 ;;=3^Nodular lymphocyte predominant Hodgkin lymphoma, unsp site
 ;;^UTILITY(U,$J,358.3,36749,1,4,0)
 ;;=4^C81.00
 ;;^UTILITY(U,$J,358.3,36749,2)
 ;;=^5001391
 ;;^UTILITY(U,$J,358.3,36750,0)
 ;;=C83.39^^169^1859^22
 ;;^UTILITY(U,$J,358.3,36750,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36750,1,3,0)
 ;;=3^Diffuse large B-cell lymphoma, extrnod and solid organ sites
 ;;^UTILITY(U,$J,358.3,36750,1,4,0)
 ;;=4^C83.39
 ;;^UTILITY(U,$J,358.3,36750,2)
 ;;=^5001580
 ;;^UTILITY(U,$J,358.3,36751,0)
 ;;=C81.09^^169^1859^62
 ;;^UTILITY(U,$J,358.3,36751,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36751,1,3,0)
 ;;=3^Nodular lymphocyte predominant Hodgkin lymphoma, extrnod & solid org site
 ;;^UTILITY(U,$J,358.3,36751,1,4,0)
 ;;=4^C81.09
 ;;^UTILITY(U,$J,358.3,36751,2)
 ;;=^5001400
 ;;^UTILITY(U,$J,358.3,36752,0)
 ;;=C81.10^^169^1859^63
 ;;^UTILITY(U,$J,358.3,36752,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36752,1,3,0)
 ;;=3^Nodular sclerosis classical Hodgkin lymphoma, unsp site
 ;;^UTILITY(U,$J,358.3,36752,1,4,0)
 ;;=4^C81.10
 ;;^UTILITY(U,$J,358.3,36752,2)
 ;;=^5001401
 ;;^UTILITY(U,$J,358.3,36753,0)
 ;;=C81.19^^169^1859^64
 ;;^UTILITY(U,$J,358.3,36753,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36753,1,3,0)
 ;;=3^Nodular sclerosis classical Hodgkin lymphoma,extrnod and solid organ sites
 ;;^UTILITY(U,$J,358.3,36753,1,4,0)
 ;;=4^C81.19
